Combining bupropion with cannabis raises real concerns, the most significant being a pharmacokinetic interaction that can increase bupropion levels in the blood and a shared ability to lower the seizure threshold. Neither substance is benign on its own in this regard, and together, the risks compound in ways that are not always obvious. The picture is further complicated by the fact that some people are prescribed bupropion specifically to help with cannabis-related issues, creating a situation where the treatment and the substance it targets interact in the body at the same time.
How Cannabis Interferes With Bupropion Metabolism
Bupropion is primarily broken down in the liver by an enzyme called CYP2B6. This is where the interaction with cannabis begins. THC, CBD, and several of their metabolites are potent inhibitors of that same enzyme. A study examining cannabinoid effects on CYP2B6-catalyzed bupropion metabolism found that THC, CBD, CBN, and the THC metabolites 11-OH-THC and THC-COO-Gluc all competitively inhibited the process, with CBD being the strongest inhibitor.1Drug Metabolism and Disposition. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions In practical terms, this means cannabis use can slow the rate at which your body clears bupropion, potentially leading to higher-than-expected drug concentrations.
This matters because bupropion’s side effects, including its most dangerous one (seizures), are dose-dependent. The drug already has a relatively narrow therapeutic window. When an outside substance effectively raises the amount of active bupropion circulating in your system, it can push you into a higher-risk zone without any change in your actual prescription dose. The effect is not limited to smoked cannabis; edibles, oils, and any CBD product could theoretically trigger the same enzyme inhibition, since CBD was the most potent CYP2B6 inhibitor among the cannabinoids tested.
The Seizure Question
Bupropion is well known for carrying a dose-dependent seizure risk. Reports of seizures associated with the drug have been documented since it first came to market, and this risk is the reason the maximum daily dose is capped and the drug carries explicit warnings about conditions that lower seizure threshold.2PubMed Central. Bupropion (Zyban, Wellbutrin SR): reports of deaths, seizures, serum sickness The risk rises with dose, with pre-existing seizure disorders, with eating disorders (which lower electrolytes), and with concurrent use of other substances that affect the seizure threshold.
Cannabis has a complicated relationship with seizures. The research on cannabinoids and epilepsy suggests that the picture depends heavily on which cannabinoid you are talking about. CBD appears to have anticonvulsant properties and has been developed into an FDA-approved treatment for certain severe seizure disorders. THC, on the other hand, has a more ambiguous profile: whole-plant cannabis, which contains THC alongside dozens of other compounds, has been reported to both contribute to and reduce seizures depending on the context.3PubMed Central. Cannabinoids and Epilepsy This means the seizure interaction is not a simple addition of two risks. If you are using a high-CBD, low-THC product, the seizure concern from the cannabis itself may be lower, but the CYP2B6 inhibition from CBD could still raise your bupropion levels. If you are using high-THC cannabis, you may face both the enzyme inhibition problem and the less predictable effects of THC on seizure threshold.
No large clinical trial has directly measured seizure rates in people taking bupropion while using cannabis. The concern is built from connecting well-established individual pieces: bupropion’s dose-dependent seizure risk, cannabis metabolites’ inhibition of the enzyme that clears bupropion, and the variable seizure-related effects of different cannabinoids. The absence of a direct trial does not make the concern hypothetical; the pharmacology is clear enough that clinicians generally treat it as a real interaction.
Psychiatric Side Effects and Psychosis Risk
Bupropion works differently from most antidepressants. It has no serotonergic activity and instead inhibits the reuptake of norepinephrine and dopamine.4PubMed Central. Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation This dopamine-boosting action is part of what makes it useful for depression, ADHD, and smoking cessation, but it also means the drug can, in certain situations, overshoot and tip into psychiatric side effects.
A systematic review of bupropion and psychosis found evidence that the drug can cause or worsen psychotic symptoms in certain subpopulations. Higher doses were more likely to be linked to these outcomes, and preexisting psychotic symptoms, substance abuse, and drug interactions all appeared to increase the risk.5PubMed Central. Bupropion-induced psychosis: folklore or a fact? A systematic review of the literature Cannabis use, particularly heavy THC consumption, is independently associated with increased risk of psychotic experiences in vulnerable individuals. When you combine a substance that raises dopamine levels (bupropion, at potentially elevated blood concentrations due to the enzyme interaction) with a substance that can itself trigger paranoia or psychotic symptoms (high-THC cannabis), the overlap is worth taking seriously.
The risk is not evenly distributed. Someone with no personal or family history of psychosis, taking a standard dose of bupropion and occasionally using a moderate amount of cannabis, is probably at low absolute risk. But someone with a history of psychotic episodes, or someone using large amounts of high-potency cannabis daily while on a higher dose of bupropion, sits in a very different category. The systematic review’s finding that substance abuse and drug interactions both independently raise the psychosis risk with bupropion suggests these factors can stack.
Can Bupropion Help With Cannabis Dependence?
This is where the story takes an ironic turn. Bupropion is one of the medications researchers have investigated as a possible treatment for cannabis use disorder, precisely because of its dopamine and norepinephrine effects. The logic is straightforward: cannabis withdrawal involves irritability, sleep problems, and cravings, and a drug that modulates the same reward circuits might help.
A small pilot study found encouraging preliminary results, with bupropion-treated participants showing less withdrawal discomfort and fewer cravings compared to placebo during cannabis cessation.6PubMed Central. Bupropion Reduces Some of the Symptoms of Marihuana Withdrawal in Chronic Marihuana Users: A Pilot Study But a larger double-blind trial comparing bupropion sustained-release to placebo found no significant effects on cannabis use or withdrawal symptoms.7PubMed Central. A preliminary trial: double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence The gap between a small pilot and a controlled trial is one of the recurring frustrations in this area of research.
A network meta-analysis comparing pharmacological and psychosocial interventions for cannabis use disorder placed bupropion among the medications that showed more adverse events than placebo without clear evidence of effectiveness, though the certainty of the evidence was rated as very low.8PubMed Central. Comparative effectiveness, safety and acceptability of pharmacological and psychosocial interventions for the treatment of cannabis use disorder: A network meta-analysis A more recent review of the neurobiological rationale behind using bupropion for stimulant and cannabis use disorders acknowledged the limited clinical evidence but suggested bupropion may still hold value as part of individualized treatment approaches, especially in patients with specific comorbidities like co-occurring depression or ADHD.9Personalized Psychiatry. Bupropion in the treatment of problematic use of and dependence on stimulants and cannabis – neurobiological rationale and clinical evidence
The honest summary is that bupropion’s theoretical appeal as a cannabis cessation aid has not translated into strong clinical evidence. If your prescriber has put you on bupropion partly for this purpose, the rationale probably has more to do with treating your depression or helping with tobacco cessation simultaneously than with a proven cannabis-specific effect.
The Overlap With Tobacco Cessation
Many cannabis users also smoke tobacco, and bupropion is one of the first-line medications for quitting smoking. This creates a practical overlap: someone may be prescribed bupropion for tobacco cessation while continuing to use cannabis, either because they were not asked about it or because they did not think it was relevant to mention.
Data from tobacco quitlines illustrate how common this situation is. In a study of callers to state quitlines, about one in four reported using marijuana in the past 30 days. Current marijuana users were actually more likely to complete multiple counseling calls than nonusers, suggesting engagement with cessation efforts was not the problem. Among those marijuana users, over 40 percent expressed a desire to quit or reduce their cannabis use as well.10Centers for Disease Control and Prevention (CDC). Marijuana Use and Adherence to Smoking Cessation Treatment Among Callers to Tobacco Quitlines This suggests a sizable group of people who are on or about to start medications like bupropion for tobacco and are simultaneously using cannabis, often without the two issues being addressed together.
From a risk standpoint, the concern is the same CYP2B6 inhibition discussed earlier. If you are taking bupropion to quit smoking and also using cannabis regularly, your bupropion blood levels may be higher than your prescriber expects. This does not necessarily mean you should stop one or the other on your own, but it does mean your prescriber needs to know about both substances to monitor you appropriately and adjust dosing if needed.
Why Disclosure Matters More Than Usual
One of the barriers to managing this interaction safely is that patients often do not tell their doctors about cannabis use. A survey-based study found that while roughly three-quarters of cannabis users reported disclosing their use to healthcare providers at least some of the time, only about 11 percent said their provider had directly asked about it. Most of the time, it was the patient who brought it up, and nearly 28 percent said the topic was never raised by either party.11PubMed Central. The role of stigma in cannabis use disclosure: an exploratory study The primary factor influencing whether someone disclosed was their comfort level with the provider.
For someone taking bupropion specifically, this disclosure gap is more consequential than for many other medications. Bupropion’s dose-dependent seizure risk and psychiatric side-effect profile mean that an unknown drug interaction raising blood levels is not just a theoretical pharmacology exercise. If you use cannabis in any form, including CBD products, and you are taking bupropion, your doctor needs that information to make safe prescribing decisions. This is not a moral conversation about drug use; it is a practical one about enzyme inhibition and dosing.
CBD Products as a Hidden Variable
The growing market for CBD-containing products adds a wrinkle that many people miss. Someone taking bupropion may not think of their daily CBD oil or gummy as “cannabis use,” especially if they purchased it at a grocery store or pharmacy. But the CYP2B6 inhibition data show that CBD was actually the most potent inhibitor of bupropion metabolism among the cannabinoids tested, with the lowest inhibition constant in the group.1Drug Metabolism and Disposition. Cannabinoid Metabolites as Inhibitors of Major Hepatic CYP450 Enzymes, with Implications for Cannabis-Drug Interactions
This means someone who has never smoked a joint in their life but takes a daily CBD supplement alongside their bupropion prescription could still be experiencing the interaction. The doses matter: a few milligrams of CBD in a low-concentration topical cream probably do not produce enough systemic absorption to meaningfully affect liver enzymes. But the 25-50 mg (or higher) oral CBD doses common in supplements and tinctures are a different story. These products are often unregulated, their actual CBD content may differ from their labels, and some contain meaningful amounts of THC as well. All of these factors make the interaction harder to predict but no less real.
Individual Variation in CYP2B6 Activity
Not everyone metabolizes bupropion at the same rate to begin with. The CYP2B6 enzyme is one of the most genetically variable drug-metabolizing enzymes in the human body. Some people carry gene variants that make them slow metabolizers, meaning they already clear bupropion more slowly and tend to have higher blood levels at any given dose. Others are ultra-rapid metabolizers who break the drug down quickly.
If you happen to be a slow CYP2B6 metabolizer and you add cannabis or CBD to the mix, the enzyme inhibition is stacking on top of an already reduced capacity to clear the drug. This could push bupropion concentrations meaningfully higher than what even the interaction alone would produce in an average metabolizer. Pharmacogenomic testing can identify your CYP2B6 status, and some clinicians are beginning to use it when prescribing bupropion, though it is far from routine. If you are a regular cannabis user starting bupropion, or vice versa, asking about this testing is reasonable.
What the Evidence Does Not Yet Cover
The biggest gap in the research is the absence of clinical studies that directly measure outcomes in people using bupropion and cannabis together. The enzyme inhibition data come from laboratory studies using human liver microsomes and recombinant enzymes, which are strong evidence for the mechanism but do not tell us the magnitude of the effect in a living person at typical cannabis doses. The seizure, psychosis, and cessation data each come from studies examining bupropion or cannabis in isolation, or in the context of other substances. Connecting these dots requires some extrapolation.
There are also no established guidelines for dose adjustment of bupropion in cannabis users. Clinicians managing this combination are largely working from pharmacological first principles and clinical judgment rather than from published dosing recommendations. This is not unusual in drug-interaction management, where formal guidance often lags behind known mechanisms, but it does mean the quality of care you receive depends heavily on whether your prescriber is aware of the interaction in the first place. Given the disclosure data showing that many providers do not proactively ask about cannabis use, the responsibility for raising the topic often falls on the patient.